{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:07:23Z","timestamp":1784866043759,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s13555-023-01067-y","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T09:02:38Z","timestamp":1702285358000},"page":"151-167","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Degree of Alignment Between Japanese Patients and Physicians on Alopecia Areata Disease Severity and Treatment Satisfaction: A Real-World Survey"],"prefix":"10.1007","volume":"14","author":[{"given":"Kouki","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simran","family":"Marwaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Piercy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8781-452X","authenticated-orcid":false,"given":"Masayo","family":"Sakaki-Yumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Ohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,11]]},"reference":[{"issue":"1","key":"1067_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1346-8138.16207","volume":"49","author":"M Fukuyama","year":"2022","unstructured":"Fukuyama M, Ito T, Ohyama M. Alopecia areata: Current understanding of the pathophysiology and update on therapeutic approaches, featuring the Japanese Dermatological Association guidelines. J Dermatol. 2022;49(1):19\u201336.","journal-title":"J Dermatol"},{"issue":"13","key":"1067_CR2","first-page":"2741","volume":"127","author":"R Tsuboi","year":"2017","unstructured":"Tsuboi R, Itami S, Manabe S, et al. Japanese Dermatological Association Alopecia areata clinical practice guidelines. Jpn J Dermatol. 2017;127(13):2741\u201362 (in Japanese).","journal-title":"Jpn J Dermatol"},{"issue":"4","key":"1067_CR3","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s13555-022-00711-3","volume":"12","author":"BA King","year":"2022","unstructured":"King BA, Senna MM, Ohyama M, et al. Defining severity in alopecia areata: current perspectives and a multidimensional framework. Dermatol Ther (Heidelb). 2022;12(4):825\u201334.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"11","key":"1067_CR4","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1046\/j.1365-4362.2002.01357.x","volume":"41","author":"E Tan","year":"2002","unstructured":"Tan E, Tay YK, Goh CL, Chin GY. The pattern and profile of alopecia areata in Singapore\u2014a study of 219 Asians. Int J Dermatol. 2002;41(11):748\u201353.","journal-title":"Int J Dermatol"},{"issue":"4","key":"1067_CR5","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/jid.2013.464","volume":"134","author":"SA Mirzoyev","year":"2014","unstructured":"Mirzoyev SA, Schrum AG, Davis MDP, Torgerson RR. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990\u20132009. J Invest Dermatol. 2014;134(4):1141\u20132.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"1067_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamadermatol.2023.0002","volume":"159","author":"A Mostaghimi","year":"2023","unstructured":"Mostaghimi A, Gao W, Ray M, et al. Trends in prevalence and incidence of alopecia areata, alopecia totalis, and alopecia universalis among adults and children in a US employer-sponsored insured population. JAMA Dermatol. 2023;159(4):411\u201318.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1067_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/1346-8138.16615","volume":"50","author":"E Campos-Alberto","year":"2023","unstructured":"Campos-Alberto E, Hirose T, Napatalung L, Ohyama M. Prevalence, comorbidities, and treatment patterns of Japanese patients with alopecia areata: a descriptive study using Japan medical data center claims database. J Dermatol. 2023;50(1):37\u201345.","journal-title":"J Dermatol"},{"issue":"6","key":"1067_CR8","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/1346-8138.16360","volume":"49","author":"E Edson-Heredia","year":"2022","unstructured":"Edson-Heredia E, Aranishi T, Isaka Y, Anderson P, Marwaha S, Piercy J. Patient and physician perspectives on alopecia areata: A real-world assessment of severity and burden in Japan. J Dermatol. 2022;49(6):575\u201383.","journal-title":"J Dermatol"},{"issue":"3","key":"1067_CR9","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1016\/j.jaad.2010.11.042","volume":"66","author":"EE Reid","year":"2012","unstructured":"Reid EE, Haley AC, Borovicka JH, Rademaker A, West DP, Colavincenzo M, et al. Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. J Am Acad Dermatol. 2012;66(3):e97-102.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1067_CR10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00403-021-02247-6","volume":"314","author":"D Tzur Bitan","year":"2022","unstructured":"Tzur Bitan D, Berzin D, Kridin K, Cohen A. The association between alopecia areata and anxiety, depression, schizophrenia, and bipolar disorder: a population-based study. Arch Dermatol Res. 2022;314(5):463\u20138.","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"1067_CR11","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1016\/j.jisp.2017.10.008","volume":"19","author":"AR Rodgers","year":"2018","unstructured":"Rodgers AR. Why finding a treatment for alopecia areata is important: a multifaceted perspective. J Investig Dermatol Symp Proc. 2018;19(1):S51\u20133.","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"7","key":"1067_CR12","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1007\/s12325-017-0542-7","volume":"34","author":"Y Renert-Yuval","year":"2017","unstructured":"Renert-Yuval Y, Guttman-Yassky E. The changing landscape of alopecia areata: the therapeutic paradigm. Adv Ther. 2017;34(7):1594\u2013609.","journal-title":"Adv Ther"},{"issue":"2","key":"1067_CR13","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/bjd\/ljac059","volume":"188","author":"B King","year":"2023","unstructured":"King B, Mostaghimi A, Shimomura Y, Zlotogorski A, Choi GS, Blume-Peytavi U, et al. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. Br J Dermatol. 2023;188(2):218\u201327.","journal-title":"Br J Dermatol"},{"key":"1067_CR14","unstructured":"US Food and Drug Administration. FDA Approves first systemic treatment for alopecia areata. 2022. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-systemic-treatment-alopecia-areata. Accessed 5 Apr 2023."},{"issue":"10","key":"1067_CR15","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1111\/1346-8138.16054","volume":"48","author":"K Kamei","year":"2021","unstructured":"Kamei K, Hirose T, Yoshii N, Tanaka A. Burden of illness, medication adherence, and unmet medical needs in Japanese patients with atopic dermatitis: a retrospective analysis of a cross-sectional questionnaire survey. J Dermatol. 2021;48(10):1491\u20138.","journal-title":"J Dermatol"},{"issue":"11","key":"1067_CR16","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes\u2014a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"1067_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. BMJ Open. 2016;6(8): e010352.","journal-title":"BMJ Open"},{"key":"1067_CR18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","volume":"9","author":"V Higgins","year":"2016","unstructured":"Higgins V, Piercy J, Roughley A, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371\u201380.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"1067_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1477-7525-1-29","volume":"1","author":"RP Snaith","year":"2003","unstructured":"Snaith RP. The Hospital Anxiety and Depression Scale. Health Qual Life Outcomes. 2003;1:29.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"1067_CR20","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67(6):361\u201370.","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"1067_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.det.2011.11.003","volume":"30","author":"MM Chren","year":"2012","unstructured":"Chren MM. The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin. 2012;30(2):231\u20136(xiii).","journal-title":"Dermatol Clin"},{"issue":"6","key":"1067_CR22","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/sj.jid.5700740","volume":"127","author":"MM Chren","year":"2007","unstructured":"Chren MM, Sahay AP, Bertenthal DS, Sen S, Landefeld CS. Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol. 2007;127(6):1351\u20137.","journal-title":"J Invest Dermatol"},{"key":"1067_CR23","volume-title":"Stata statistical software: release 17","author":"StataCorp","year":"2021","unstructured":"StataCorp. Stata statistical software: release 17. College Station: StataCorp LLC; 2021."},{"key":"1067_CR24","unstructured":"US Department of Health and Human Services. Summary of the HIPAA privacy rule. 2022. https:\/\/www.hhs.gov\/sites\/default\/files\/ocr\/privacy\/hipaa\/understanding\/summary\/privacysummary.pdf. Accessed 29 May 2023."},{"issue":"6","key":"1067_CR25","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/1346-8138.16364","volume":"49","author":"T Ito","year":"2022","unstructured":"Ito T, Kamei K, Yuasa A, et al. Health-related quality of life in patients with alopecia areata: Results of a Japanese survey with norm-based comparisons. J Dermatol. 2022;49(6):584\u201393.","journal-title":"J Dermatol"},{"issue":"2","key":"1067_CR26","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jaad.2021.08.043","volume":"86","author":"BA King","year":"2022","unstructured":"King BA, Mesinkovska NA, Craiglow B, et al. Development of the alopecia areata scale for clinical use: results of an academic-industry collaborative effort. J Am Acad Dermatol. 2022;86(2):359\u201364.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1067_CR27","first-page":"e404","volume":"115","author":"KJ Juarez-Rendon","year":"2017","unstructured":"Juarez-Rendon KJ, Rivera Sanchez G, Reyes-Lopez MA, et al. Alopecia areata. Current situation and perspectives. Arch Argent Pediatr. 2017;115(6):e404\u201311.","journal-title":"Arch Argent Pediatr"},{"issue":"6","key":"1067_CR28","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1159\/000501940","volume":"5","author":"AK Gupta","year":"2019","unstructured":"Gupta AK, Carviel JL, Foley KA, et al. Monotherapy for alopecia areata: a systematic review and network meta-analysis. Skin Appendage Disord. 2019;5(6):331\u20137.","journal-title":"Skin Appendage Disord"},{"issue":"7","key":"1067_CR29","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.autrev.2016.02.021","volume":"15","author":"T Yoshimasu","year":"2016","unstructured":"Yoshimasu T, Furukawa F. Modified immunotherapy for alopecia areata. Autoimmun Rev. 2016;15(7):664\u20137.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"1067_CR30","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","volume":"15","author":"M Oray","year":"2016","unstructured":"Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457\u201365.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"1067_CR31","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s12325-020-01561-1","volume":"38","author":"A Igarashi","year":"2021","unstructured":"Igarashi A, Bekker Hansen B, Langer J, et al. Preference for oral and injectable GLP-1 RA therapy profiles in Japanese patients with type 2 diabetes: a discrete choice experiment. Adv Ther. 2021;38(1):721\u201338.","journal-title":"Adv Ther"},{"issue":"7","key":"1067_CR32","doi-asserted-by":"publisher","first-page":"A568","DOI":"10.1016\/j.jval.2013.08.1521","volume":"16","author":"N Barclay","year":"2013","unstructured":"Barclay N, Tarallo M, Hendrikx T, Marett S. Patient preference for oral versus injectable and intravenous methods of treatment for rheumatoid arthritis. Value Health. 2013;16(7):A568.","journal-title":"Value Health"},{"issue":"9","key":"1067_CR33","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.7326\/M22-1460","volume":"175","author":"LM DeTora","year":"2022","unstructured":"DeTora LM, Toroser D, Sykes A, et al. Good publication practice (GPP) guidelines for company-sponsored biomedical research: 2022 update. Ann Intern Med. 2022;175(9):1298\u2013304.","journal-title":"Ann Intern Med"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01067-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-01067-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01067-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T14:39:40Z","timestamp":1706625580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-01067-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,11]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1067"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-01067-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,11]]},"assertion":[{"value":"15 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kouki Nakamura, Kazumasa Kamei and Masayo Sakaki-Yumoto are employed by Pfizer Japan Inc. and hold stock in Pfizer Inc. Pfizer Inc. is a global manufacturer\/distributor of ritlecitinib, a JAK3\/TEC family kinase inhibitor which is approved for alopecia areata by representative medical agencies, including the U.S. Food and Drug Administration, European Medicines Agency and Pharmaceuticals and Medical Devices Agency (Japan). Manabu Ohyama receives lecture fees from Eli Lilly Japan and Pfizer Inc.; advisory fees from Eli Lilly Japan, Pfizer Inc., Maruho Co., Bristol Myers Squibb Japan., Taisho Pharmaceutical Co., AbbVie GK. and ROHTO Pharmaceutical Co.; and research grants not directory related with this study from Maruho Co., Shiseido Co, Advantest Corp. and Sun Pharma Japan Ltd. Jenny Austin, Simran Marwaha, James Piercy and Peter Anderson are employed by Adelphi Real World.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Patients and physicians provided informed consent for use of their anonymized and aggregated data for research and publication in scientific journals. Data were collected anonymously; all data were aggregated and de-identified before receipt. The DSP was performed in accordance with relevant legislation, including the US Health Insurance Portability and Accountability Act (HIPAA) 1996 []. It was submitted to the Western Institutional Review Board for methodological review in 2019 (study protocol no.: AG8446) and was granted an exemption.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}